KESIMPTA: payments to doctors
Payments that named KESIMPTA as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $4.9M
- Providers
- 8,919
- Transactions
- 160,843
- Average per transaction
- $30
The per-transaction average — $30 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 8,919 providers the average total is $549, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Novartis | $4,708,511 | 96.1% |
| Novartis Pharma AG | $191,460 | 3.9% |